Sézary syndrome: immunocytological and cytochemical variability of Sézary cells.
The characteristic large cells in the blood of a patient with Sézary syndrome underwent immunocytological and cytochemical changes during polychemotherapy, which caused transient regression of skin lesions. Tartrate-resistant acid phosphatase was demonstrable in a few cells only after chemotherapy; initially, only 2% T cells and 26% B cells could be demonstrated in the blood by immunocytological methods; after cytostatic therapy, 35% T cells but no B cells were detected.
D000135:Acid Phosphatase / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects*; D002467:Cell Nucleus; D003520:Cyclophosphamide / Q000627:therapeutic use; D005448:Fluocortolone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000097:blood*; D013601:T-Lymphocytes / Q000187:drug effects*; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D005448:Fluocortolone; D003520:Cyclophosphamide; D000135:Acid Phosphatase